We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked

Affiliations

Editorial

Yasuhiro Chikaishi et al. J Thorac Dis. 2018 Sep.

. 2018 Sep;10(Suppl 26):S3257-S3259.

doi: 10.21037/jtd.2018.08.63.

¹ Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
Yang CJ, Gu L, Shah SA, Yerokun BA, D'Amico TA, Hartwig MG, Berry MF. Yang CJ, et al. Lung Cancer. 2018 Jan;115:75-83. doi: 10.1016/j.lungcan.2017.11.021. Epub 2017 Nov 23. Lung Cancer. 2018. PMID: 29290266

1. Grossi F, Kubota K, Cappuzzo F, et al. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 2010;15:1102-12 10.1634/theoncologist.2010-0322 - DOI - PMC - PubMed
1. Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014;120 Suppl 23:3781-92. 10.1002/cncr.29045 - DOI - PMC - PubMed
1. Soo RA, Stone ECA, Cummings KM, et al. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol 2017;12:1183-209. 10.1016/j.jtho.2017.05.019 - DOI - PubMed
1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed
1. Yoneda K, Imanishi N, Ichiki Y, et al. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). J UOEH 2018;40:173-89. 10.7888/juoeh.40.173 - DOI - PubMed